Loading…
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $62M | $-109M | $-102M | $-140M | -29.3% | 48.3% | -22.0% |
| 2024 | $42M | $-143M | $-130M | $-132M | -65.3% | 15.2% | 28.1% |
| 2023 | $37M | $-112M | $-102M | $-120M | -40.2% | 46.9% | -5.9% |
| 2022 | $25M | $-109M | $-108M | $-117M | -43.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 24.86 | 36.53 | 42.07 | 62.38 |
| Operating Revenue | - | 24.86 | 36.53 | 42.07 | 62.38 |
| Operating Expense | - | 135.93 | 150.70 | 187.66 | 173.67 |
| Research And Development | - | 105.91 | 115.20 | 143.92 | 132.16 |
| Selling General And Administration | - | 30.02 | 35.50 | 43.75 | 41.51 |
| Total Expenses | - | 135.93 | 150.70 | 187.66 | 173.67 |
| Operating Income | - | -111.07 | -114.17 | -145.60 | -111.29 |
| Total Operating Income As Reported | - | -111.07 | -114.17 | -145.60 | -111.29 |
| EBITDA | - | -109.46 | -111.76 | -143.10 | -109.01 |
| Normalized EBITDA | - | -109.46 | -111.76 | -143.10 | -109.01 |
| EBIT | - | -111.07 | -114.17 | -145.60 | -111.29 |
| Interest Income | - | 1.46 | 6.62 | 7.89 | 5.63 |
| Net Interest Income | - | 1.46 | 6.62 | 7.89 | 5.63 |
| Other Non Operating Income Expenses | - | 1.49 | 5.94 | 7.61 | 4.07 |
| Other Income Expense | - | 1.49 | 5.94 | 7.61 | 4.07 |
| Interest Income Non Operating | - | 1.46 | 6.62 | 7.89 | 5.63 |
| Net Non Operating Interest Income Expense | - | 1.46 | 6.62 | 7.89 | 5.63 |
| Pretax Income | - | -108.12 | -101.61 | -130.09 | -101.59 |
| Tax Provision | - | 0.05 | 0.13 | 0.21 | 0 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -108.18 | -101.74 | -130.30 | -101.59 |
| Net Income From Continuing And Discontinued Operation | - | -108.18 | -101.74 | -130.30 | -101.59 |
| Net Income From Continuing Operation Net Minority Interest | - | -108.18 | -101.74 | -130.30 | -101.59 |
| Net Income | - | -108.18 | -101.74 | -130.30 | -101.59 |
| Net Income Common Stockholders | - | -108.18 | -101.74 | -130.30 | -101.59 |
| Net Income Including Noncontrolling Interests | - | -108.18 | -101.74 | -130.30 | -101.59 |
| Normalized Income | - | -108.18 | -101.74 | -130.30 | -101.59 |
| Diluted NI Availto Com Stockholders | - | -108.18 | -101.74 | -130.30 | -101.59 |
| Basic Average Shares | 62.11 | 87.82 | 94.57 | 109.23 | - |
| Diluted Average Shares | 62.11 | 87.82 | 94.57 | 109.23 | - |
| Reconciled Depreciation | - | 1.61 | 2.42 | 2.50 | 2.28 |
| General And Administrative Expense | - | 30.02 | 35.50 | 43.75 | 41.51 |
| Other Gand A | - | 30.02 | 35.50 | 43.75 | 41.51 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Tango Therapeutics, Inc.this co. | TNGX | $3.2B | -31.54 | 9.26 | -29.3% | -28.67 |
| Beam Therapeutics Inc. | BEAM | $3.4B | -42.24 | 2.73 | -6.5% | -8.96 |
| Denali Therapeutics Inc. | DNLI | $3.2B | -6.24 | 3.15 | -50.6% | -5.60 |
| Haemonetics Corporation | HAE | $3.2B | 32.62 | 3.99 | 12.2% | 15.47 |
| Relay Therapeutics, Inc. | RLAY | $3.2B |
| - |
| - |
| - |
| - |
| - |
| - |
| -11.46 |
| 5.59 |
| -48.8% |
| -10.42 |
| Option Care Health, Inc. | OPCH | $3.2B | 15.18 | 2.38 | 15.6% | 10.27 |
| Alignment Healthcare, Inc. | ALHC | $3.1B | - | 17.38 | -0.4% | 62.69 |
| Dyne Therapeutics, Inc. | DYN | $3.0B | -6.82 | 3.13 | -45.9% | -5.30 |
| Warby Parker Inc. | WRBY | $3.0B | 1803.71 | 8.05 | 0.4% | 64.67 |
| Peer Median | - | -6.24 | 3.57 | -3.4% | 2.49 | |